Patients with either advanced triple-negative breast cancer [TNBC] and a maximum of two lines of systemic therapy or hormone receptor-positive/human epidermal growth factor receptor 2-negative [HR+/HER2−] breast cancer and a maximum of three lines of systemic therapy, participated in semi-structured concept elicitation interviews. Here, NR4A1 is linked to triple-negative breast carcinoma.